To date, more than 10 antibody-drug conjugates (ADCs) have been approved by the U.S. Food and Drug Administration (FDA) and contribute to the medical community.
Interestingly, all of them are manufactured using chemical conjugation techniques [1]. This demonstrates that chemical conjugation is the primary approach to ADC manufacturing. Compared to other conjugation techniques (e.g., genetic engineering or enzymatic), chemical conjugation has the advantage of a relatively simple chemistry, manufacturing, and control (CMC) for ADC, prompting pharmaceutical companies to choose this technique for ADC projects [2].
To better understand this advantage, this article provides an overview of established full chemical conjugation methods that have already been applied in the scale-up phase for ADC production.
Authors:
Corresponding Author: Yutaka Matsuda, Ph.D. E-mail: Yutaka Matsuda, Ph.D.
Key terms: ADC, bioconjugation, differential antigen expression, simultaneous delivery of drugs
Published In: ADC Review| Journal of Antibody-drug Conjugates
DOI: https://doi.org/10.14229/jadc.2023.01.05.002.
How to cite:
Matsuda Y.1 Recent advances in antibody-drug conjugates produced using chemical conjugation technology – J. ADC. January 5, 2023. DOI: 10.14229/jadc.2023.01.05.002.
1Ajinomoto Bio-Pharma Services, San Diego, CA 92121
Last Editorial Review: December 26, 2022
Article History:
- Original Manuscript Received December 15, 2022
- Review results received December 20, 2022
- Manuscript accepted for publication December 27, 2023
Featured image: Bioconjugation. Photo courtesy: © 2016 – 2023 – Ajinomoto Bio-Pharma Services, San Diego. Used with permission.
